K Number
K150673
Date Cleared
2015-08-21

(158 days)

Product Code
Regulation Number
888.3080
Reference & Predicate Devices
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The SYNFIX Evolution Secured System is a stand-alone anterior interbody fusion device indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis at the interior of the spacer component of the SYNFIX Evolution can be packed with autograft.

DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.

Device Description

The SYNFIX Evolution Secured Spacer System is a combination radiolucent and radiopaque intervertebral body fusion device. Four screws are inserted through the anteriorly-located plate into the adjacent vertebral bodies. The screws lock securely to the plate using a tapered-thread locking mechanism. The SYNFIX Evolution Secured Spacer System is available as assembled components in various heights and geometries to suit individual pathology and anatomical conditions.

AI/ML Overview

The provided text is a 510(k) summary for the SYNFIX® Evolution Secured Spacer System and does not contain information about an AI-powered medical device or studies related to AI performance. Therefore, I cannot extract the requested information regarding acceptance criteria and studies for an AI device.

The document discusses a traditional medical device, an intervertebral body fusion device, and its substantial equivalence to predicate devices based on mechanical testing and Finite Element Analysis. There is no mention of AI, machine learning, or algorithms.

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of a stylized human figure with three faces in profile, representing the department's focus on health and well-being. The logo is simple, clean, and easily recognizable.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

August 21, 2015

Synthes (USA) Products LLC Mr. Eugene Bang Regulatory Affairs Associate 325 Paramount Drive Raynham, Massachusetts 02767

Re: K150673

Trade/Device Name: SYNFIX® Evolution Secured Spacer System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: OVD Dated: July 31, 2015 Received: August 3, 2015

Dear Mr. Bang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

Page 2 - Mr. Eugene Bang

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

K150673

Page 1 of 1

510(k) Number (if known) K150673

B 667 B

Device Name SYNFIX® Evolution Secured Spacer System

Indications for Use (Describe)

The SYNFIX Evolution Secured System is a stand-alone anterior interbody fusion device indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis at the interior of the spacer component of the SYNFIX Evolution can be packed with autograft.

DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment.

Type of Use (Select one or both, as applicable)
---------------------------------------------------

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

Submitter:Synthes USA Products, LLC.325 Paramount DriveRaynham, MA 02767
Contact Person:Eugene BangRegulatory Affairs AssociateTelephone: (508) 977-3966Fax: (508) 828-3797
Date Prepared:March 13, 2015
Trade Name:SYNFIX® Evolution Secured Spacer System
Device Class:Class II
Product Code:OVD
Common Name:Intervertebral Fusion Device With Integrated Fixation, Lumbar
Classification Name:Intervertebral Body Fusion Device
Regulation Number:21 CFR 888.3080
Classification Panel:Orthopaedic and Rehabilitation Devices Panel (87)
Primary Predicate:Synthes SYNFIX-LR (K072253)
Additional Predicates:Synthes Zero-P (K072981)Synthes SYNCAGE Evolution (K122639)Synthes SYNFIX Lateral (K131276)Medtronic Sovereign (K121982)Centinel Spine Midline II (K141942)
Device Description:The SYNFIX Evolution Secured Spacer System is a combinationradiolucent and radiopaque intervertebral body fusion device. Fourscrews are inserted through the anteriorly-located plate into the adjacentvertebral bodies. The screws lock securely to the plate using a tapered-thread locking mechanism.The SYNFIX Evolution Secured Spacer System is available asassembled components in various heights and geometries to suitindividual pathology and anatomical conditions.
Indications:The SYNFIX Evolution Secured Spacer System is a stand-alone anteriorinterbody fusion device indicated for use in patients with degenerativedisc disease (DDD) at one or two contiguous levels from L2 to S1. Thesepatients may also have up to Grade I spondylolisthesis at the involvedlevel(s). The interior of the spacer component of the SYNFIX Evolutioncan be packed with autograft.DDD is defined as back pain of discogenic origin with degeneration ofthe disc confirmed by history and radiographic studies. These patientsshould be skeletally mature and have had six months of non-operativetreatment.
Materials:The spacer component is manufactured from medical grade PEEKOPTIMA LT-1 (ASTM F2026) with tantalum alloy markers (ASTM F560). The plate and screws are manufactured from Ti-6Al-7Nb (ISO5832).
Comparison toPredicate Device:The substantial equivalence of the subject device to the predicatesidentified above is based upon the equivalence of intended use, design(fundamental scientific technology), materials, performance, sterility,and biocompatibility.
Performance Data:Performance data in the form of Finite Element Analysis and mechanicaltesting per ASTM F2077 (compression, compression shear) wasperformed to provide data to support a substantial equivalencedetermination. The Finite Element Analysis and mechanical testingwas performed to characterize the properties and functionality ofthe system, as well as to allow comparison with established acceptancecriteria.
Clinical TestSummary:No clinical data was necessary to demonstrate substantial equivalence,nor safety and effectiveness of this system.
Conclusion:Based on the predicate comparison of intended use, indications,technological characteristics, and device performance, the SYNFIXEvolution Secured Spacer System has demonstrated substantialequivalence to the identified predicate device systems.

{4}------------------------------------------------

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.